Amgen was granted exclusive access to an antigen under development by Tetragenetics. The deal gives Amgen the right to use the antigen, which causes the immune system to generate antibodies, for drug development.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan